Have to agree, NZ.
A deal increasing the cash on hand, reducing costs etc makes this stock a lot safer in the rather ‘unsafe and unpredictable’ biotech world.
The thought of no sudden TH relating to a CR is a promising thought.
Looking forward to the details. I hope it isn’t underwhelming.
Add to My Watchlist
What is My Watchlist?
